Sofpironium bromide

Sofpironium bromide

Clinical data
Trade names	Ecclock
Other names	BBI 4000
Routes of administration	Topical gel
Legal status
Legal status	Rx-only (Japan)
Identifiers
IUPAC name [(3R)-1-(2-Ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
CAS Number	1628106-94-4
PubChem CID	86301316
ChemSpider	52085312
UNII	7B2Y1932XU
KEGG	D10989
ChEMBL	ChEMBL3707223
Chemical and physical data
Formula	C22H32BrNO5
Molar mass	470.404 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
InChI InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1 Key:FIAFMTCUJCWADZ-JOFREBOKSA-M

Sofpironium bromide (trade name Ecclock; development code BBI-4000) is a drug used to treat hyperhidrosis (excessive sweating). It was approved in Japan in 2020 as a 5% gel for the treament of primary axillary hyperhidrosis (PAH).

Sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting M₃ muscarinic receptors in eccrine glands. It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide, meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.